To determine circulating levels of
adipocytokines, especially the recently characterized
visfatin, and the fat-derived factor
retinol-binding protein-4 (RBP-4) in HIV-infected subjects and their respective changes following treatment with
highly active antiretroviral therapy (
HAART). Fourteen HIV-positive,
HAART-naïve subjects were compared with 10 HIV-negative healthy controls and reassessed after a 1-year treatment with
HAART. Plasma
visfatin and RBP-4 were determined by ELISA, whereas
leptin and
adiponectin by RIA. Body composition was measured with dual X-ray absorptiometry (DXA). Homeostasis model assessment (HOMA-IR) was assessed using
insulin and
glucose levels.
Visfatin and RBP-4 levels in HIV-positive subjects were comparable with those of HIV-negative controls before treatment with
HAART. Treatment with
HAART for 12 months resulted in a 6.9-fold and 7.1-fold increase of
visfatin and RBP-4 levels (+54.0 +/- 9.7 ng mL(-1), P < 0.0001 and +95.3 +/- 31.7 ng mL(-1), P < 0.01), respectively.
Leptin (-2.7 +/- 1.6 ng mL(-1), P = 0.054) was unchanged and
adiponectin (-2.8 +/- 0.7 microg mL(-1), P < 0.01) decreased. Changes of
visfatin concentrations correlated significantly with the increases of RBP-4 (r = 0.78, P = 0.001), fat-free mass (FFM, r = 0.75, P < 0.05) and change of HOMA-IR (r = 0.64, P < 0.05). Parameters of
glucose metabolism and body fat mass were unchanged during the observation period. Treatment with
HAART induced a pronounced increase of plasma
visfatin and RBP-4 as well as a decrease of
adiponectin in HIV-infected patients on
HAART. Although
body weight, fat mass and parameters of
glucose metabolism remained stable, the changes in the
adipocytokines might herald subsequent alterations of these parameters.